Estimated Annual Spending on Aducanumab in the US Medicare Program.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35977233.
- Also identified by DOI 10.1001/jamahealthforum.2021.4495 and PMC identifier 8903103.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.
Medical subject headings
- Cognitive Dysfunction
- Dementia